📊 TRAW Key Takeaways
Is Traws Pharma, Inc. (TRAW) a Good Investment?
Traws Pharma exhibits critical financial distress with negative stockholders' equity (-$5.3M), severe liquidity constraints (0.43x current ratio), and unsustainable cash burn (-$5.2M quarterly FCF). Despite exceptional revenue growth from a near-zero baseline, operating losses of -$249% margin and deteriorating net profitability (-25.1% YoY) indicate no viable business model; with only $3.1M cash remaining against quarterly burn rates, the company faces imminent insolvency without immediate capital infusion.
Traws Pharma, Inc. Key Strengths (TRAW)
- Exceptional YoY revenue growth of 1134.5% indicates market traction despite minimal baseline
- Maintains $3.1M cash reserve providing limited operational runway
- Pharmaceutical sector exposure offers potential for transformational product development
TRAW Stock Risks: Traws Pharma, Inc. Investment Risks
- Technically insolvent: liabilities ($13.5M) exceed assets ($8.2M) by $5.3M
- Liquidity crisis: 0.43x current ratio cannot cover short-term obligations
- Unsustainable burn rate: $5.2M quarterly FCF burn with only $3.1M cash (~6 months runway)
- Deteriorating profitability: -254.7% net margin with net income declining 25.1% YoY despite revenue growth
- Operating losses of $6.9M on $2.8M revenue indicate pre-commercialization stage without viable economics
- Revenue growth quality poor: expansion from near-zero baseline not indicative of sustainable business model
- High insider transaction frequency (11 Form 4 filings) may indicate opportunistic selling/option exercises
Key Metrics to Watch
- Cash balance depletion rate and insolvency timeline
- Operating cash flow trajectory and burn rate acceleration/deceleration
- Stockholders' equity recovery vs. further deterioration
- Revenue sustainability and gross margin achievement
- Capital raise announcements, debt restructuring, or strategic acquisition announcements
Traws Pharma, Inc. (TRAW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
TRAW Profit Margin, ROE & Profitability Analysis
TRAW vs Healthcare Sector: How Traws Pharma, Inc. Compares
How Traws Pharma, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Traws Pharma, Inc. Stock Overvalued? TRAW Valuation Analysis 2026
Based on fundamental analysis, Traws Pharma, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Traws Pharma, Inc. Balance Sheet: TRAW Debt, Cash & Liquidity
TRAW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Traws Pharma, Inc.'s revenue has grown significantly by 28% over the 5-year period, indicating strong business expansion. The most recent EPS of $-22.57 indicates the company is currently unprofitable.
TRAW Revenue Growth, EPS Growth & YoY Performance
TRAW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $57.0K | -$4.7M | $-5.64 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Traws Pharma, Inc. Dividends, Buybacks & Capital Allocation
TRAW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Traws Pharma, Inc. (CIK: 0001130598)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TRAW
What is the AI rating for TRAW?
Traws Pharma, Inc. (TRAW) has an AI grade of D with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TRAW's key strengths?
Claude: Exceptional YoY revenue growth of 1134.5% indicates market traction despite minimal baseline. Maintains $3.1M cash reserve providing limited operational runway.
What are the risks of investing in TRAW?
Claude: Technically insolvent: liabilities ($13.5M) exceed assets ($8.2M) by $5.3M. Liquidity crisis: 0.43x current ratio cannot cover short-term obligations.
What is TRAW's revenue and growth?
Traws Pharma, Inc. reported revenue of $2.8M.
Does TRAW pay dividends?
Traws Pharma, Inc. does not currently pay dividends.
Where can I find TRAW SEC filings?
Official SEC filings for Traws Pharma, Inc. (CIK: 0001130598) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TRAW's EPS?
Traws Pharma, Inc. has a diluted EPS of $-0.53.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is TRAW's fundamental grade?
Based on our AI fundamental analysis in June 2026, Traws Pharma, Inc. has a D grade with 95% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is TRAW stock overvalued or undervalued?
Valuation metrics for TRAW: ROE of N/A (sector avg: 15%), net margin of -254.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is TRAW's AI grade for 2026?
Our dual AI analysis gives Traws Pharma, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TRAW's free cash flow?
Traws Pharma, Inc.'s operating cash flow is $-2.6M, with capital expenditures of $2.6M. FCF margin is -185.0%.
How does TRAW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -254.7% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.43 (avg: 2).